Compare Roundhill Magnificent Seven ETF (MAGS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $67.07, while Regeneron Pharmaceuticals Inc trades at $671.87 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Roundhill Magnificent Seven ETF pays none, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| MAGS | REGN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.94 | $812.27 |
52-Week Low | $55.39 | $545.46 |
Market Cap | — | $70.47B |
Enterprise Value | — | $64.42B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS, the Roundhill Magnificent Seven ETF, trades at $66.93, showing minimal daily movement with a neutral technical signal. It holds an equal-weight basket of seven mega-cap tech stocks, benefiting from AI-driven market trends but facing concentration risks. Recent news highlights AI spending shifts and broadening market gains beyond chipmakers.
The ETF's outlook hinges on AI adoption and hyperscaler performance, with potential from compressed valuations, but risks include overconcentration and high expectations. Institutional interest remains strong, though analyst views are mixed amid sector rotation.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
